KM estimates of PFS from diagnosis by therapy group. Log-rank statistics were used to compare the 4 therapy groups. No significant difference was observed between the RHCVAD and RCHOP+HDT/ASCR therapy groups (P = .50), or between the RHCVAD (P = .57), RCHOP+HDT/ASCR (P = .96), and RHCVAD+HDT/ASCR therapy groups. Patients in the RHCVAD (P < .001), RHCVAD+HDT/ASCR (P = .004), and RCHOP+HDT/ASCR (P < .001) therapy groups had significantly superior PFS compared with patients in the RCHOP therapy group. Median follow-up: 33 months; 3-year PFS: RHCVAD = 58% (95% CI: 44%, 69%), RCHOP+HDT/ASCR = 56% (95% CI: 33%, 74%), RHCVAD+HDT/ASCR = 55% (95% CI: 22%, 79%), RCHOP = 18% (95% CI: 6%, 36%).